These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 10450539

  • 1. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
    Jastrzebska M, Torbus-Lisiecka B, Pieczul-Mróz J, Chelstowski K, Kopciewicz J, Naruszewicz M.
    Int J Clin Pharmacol Res; 1999; 19(1):19-25. PubMed ID: 10450539
    [Abstract] [Full Text] [Related]

  • 2. Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia.
    Krüger B.
    Int J Clin Pharmacol Res; 1994; 14(5-6):177-83. PubMed ID: 7672874
    [Abstract] [Full Text] [Related]

  • 3. [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].
    Freyberger H, Schifferdecker E, Schatz H.
    Med Klin (Munich); 1994 Nov 15; 89(11):594-7, 633. PubMed ID: 7815987
    [Abstract] [Full Text] [Related]

  • 4. [Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate].
    Fonseca FA, Novazzi JP, Cendoroglo MS, Duarte M, Almeida Pinto LE, Rabelo LM, da Rocha Martinez TL.
    Arq Bras Cardiol; 1996 Jan 15; 66(1):33-5. PubMed ID: 8731322
    [Abstract] [Full Text] [Related]

  • 5. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
    Kovács I, Tarján J, Császár A.
    Orv Hetil; 2001 Apr 15; 142(15):775-9. PubMed ID: 11367862
    [Abstract] [Full Text] [Related]

  • 6. The effect of Etofibrate (Lipo-Merz) on "in vitro" cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans.
    Horváth M, Varsányl M, Jovanovich N, Romics L, Gerö S.
    Allergol Immunopathol (Madr); 1990 Apr 15; 18(2):95-9. PubMed ID: 2371944
    [Abstract] [Full Text] [Related]

  • 7. [Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
    Espinosa RA, Rodríguez-Roa E, Nagy E, Mijares ME, Rodríguez-Larralde A, Gil A, Lundberg U, Carvajal Z, Castillo L, Arocha-Piñango CL.
    Invest Clin; 2006 Mar 15; 47(1):35-48. PubMed ID: 16562643
    [Abstract] [Full Text] [Related]

  • 8. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.
    Kowalski M.
    J Physiol Pharmacol; 2001 Aug 15; 52(1 Suppl 1):3-31. PubMed ID: 11795863
    [Abstract] [Full Text] [Related]

  • 9. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
    Dobiásová M, Frohlich J.
    Vnitr Lek; 2000 Mar 15; 46(3):152-6. PubMed ID: 11048517
    [Abstract] [Full Text] [Related]

  • 10. [Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia].
    Vázquez-Chávez C, Salinas-Orozco S, Gómez-Díaz RA, Rosso-Juárez MM, Moreno-Vázquez K, Nissen-Torres T, Argüero-Sánchez R.
    Rev Invest Clin; 1998 Mar 15; 50(6):491-6. PubMed ID: 10070221
    [Abstract] [Full Text] [Related]

  • 11. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
    Wu TJ, Ou HY, Chou CW, Hsiao SH, Lin CY, Kao PC.
    Ann Clin Lab Sci; 2007 Mar 15; 37(2):158-66. PubMed ID: 17522372
    [Abstract] [Full Text] [Related]

  • 12. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V, Souki A, Cano-Ponce C, Bermúdez-Arias F, Mengual-Moreno E, Leal-Gonzalez E, Lemus-Antepaz M, de Bravo MC, de Díaz AA, de Pirela NL, Cano-Peñaloza R, Puche-Medina G, Arraiz N, Reyna-Villazmil N, Contreras F, Israili ZH, Valasco M.
    Am J Ther; 2007 Mar 15; 14(2):213-20. PubMed ID: 17414592
    [Abstract] [Full Text] [Related]

  • 13. Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII.
    Fincham JE, Quack G, Wülfroth P, Benadé AJ.
    Arzneimittelforschung; 1996 May 15; 46(5):519-25. PubMed ID: 8737639
    [Abstract] [Full Text] [Related]

  • 14. [Atherosclerosis treatment with etofibrate retard. New perspectives].
    Degenring FH, Schatton W, Hotz W.
    Fortschr Med; 1983 Aug 11; 101(30):1391-6. PubMed ID: 6618402
    [Abstract] [Full Text] [Related]

  • 15. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.
    Sarafidis PA, Lasaridis AN, Nilsson PM, Mouslech TF, Hitoglou-Makedou AD, Stafylas PC, Kazakos KA, Yovos JG, Tourkantonis AA.
    Metabolism; 2005 Sep 11; 54(9):1236-42. PubMed ID: 16125536
    [Abstract] [Full Text] [Related]

  • 16. [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study].
    dos Santos JE, Loures-Vale AA, Novazzi JP, Rabelo LM, Martinez TL.
    Arq Bras Cardiol; 1996 Dec 11; 67(6):419-22. PubMed ID: 9246832
    [Abstract] [Full Text] [Related]

  • 17. [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans].
    Dembińska-Kieć A, Kostka-Trabka E, Grodzińska L, Bieroń K, Kedzior A, Basista M, Zmuda A, Trabka E, Slawiński M, Czarnecka H.
    Fortschr Med; 1989 Jul 10; 107(20):450-2. PubMed ID: 2767596
    [Abstract] [Full Text] [Related]

  • 18. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M.
    J Cardiovasc Pharmacol Ther; 2002 Oct 10; 7(4):219-26. PubMed ID: 12490967
    [Abstract] [Full Text] [Related]

  • 19. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 10; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 20. [Effectiveness of ciprofibrate. Open study in a Portuguese population].
    Silva JM, Branco MC, Pereira M, Figueiredo H, Jesus LC, de Moura JP, Ferreira MR, Serra e Silva P.
    Rev Port Cardiol; 1995 Apr 10; 14(4):313-22, 284. PubMed ID: 7612280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.